Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin/ezetimibe effects on CD8+ T-cell senescence in type 2 diabetes with hypercholesterolemia
KCT0003477Phase 3Completed
- Sponsor
- Yuhan
- Start
- May 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rosuvastatin, ezetimibe in type 2 diabetes mellitus (T2DM), hypercholesterolemia, sponsored by Yuhan. Started May 2019; status: completed.
02
Drugs
rosuvastatinezetimibe
03
Conditions
type 2 diabetes mellitus (T2DM)hypercholesterolemia
Beyond the preview
Go deeper on KCT0003477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003477.